Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type Conference

Newland, MR, Weinstein, A, Kerdel, F. (2002). Rapid response to infliximab in severe pustular psoriasis, von Zumbusch type . INTERNATIONAL JOURNAL OF DERMATOLOGY, 41(7), 449-452. 10.1046/j.1365-4362.2002.01543.x

cited authors

  • Newland, MR; Weinstein, A; Kerdel, F

authors

abstract

  • Tumor necrosis factor-alpha (TNF-α) is a chemokine secreted by T cells which is thought to play a critical role in the pathophysiology of psoriasis. The monoclonal antibody, infliximab, complexes with TNF-α, rendering it inactive. A recent clinical trials has reported the clinical benefit and safety of infliximab in moderate to severe plaque psoriasis. We report a case of rapid response and clinical benefit using infliximab in severe pustular psoriasis of von Zumbusch.

publication date

  • August 29, 2002

published in

Digital Object Identifier (DOI)

start page

  • 449

end page

  • 452

volume

  • 41

issue

  • 7